At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
Sorafenib (BAY-43-9006)drug
Likely dose
Sorafenib (BAY-43-9006) 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy
In Brief
A Phase 2 clinical trial evaluating Sorafenib (BAY-43-9006) for Sarcoma, Soft Tissue. Completed, enrolled 69 participants across 1 site.
Detailed Summary
The aim of this study (\*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients. (\*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Soft Tissue
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedDec 2006
Primary CompletionJun 2010
Study CompletionSep 2010
TodayJul 2026
First PostedDec 4, 2006
Enrollment StartNov 1, 2006
Primary CompletionJun 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.6 years ago
Interventions
Sorafenib (BAY-43-9006)drug
800 mg/die orally on a continuous basis